CD40 ligand-specific antibodies synergize with cyclophosphamide to promote long-term transplantation tolerance across MHC barriers but inhibit graft-vs-leukemia effects of transplanted cells

Experimental Hematology

Volumn 31, Issue 1, 2003, Pages 81-88

  Prigozhina, Tatyana B ^a   Gurevitch, Olga ^a   Elkin, Gregory ^a   Morecki, Shoshana ^a   Yakovlev, Elena ^a   Slavin, Shimon ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; CD40 LIGAND MONOCLONAL ANTIBODY; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ARTICLE; BONE MARROW TRANSPLANTATION; CELL TRANSPLANTATION; CHIMERA; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; GRAFT REJECTION; GRAFT VERSUS LEUKEMIA EFFECT; IMMUNE RESPONSE; IRRADIATION; LEUKEMIA; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SAFETY; SKIN ALLOGRAFT; SKIN GRAFT; SURVIVAL; TREATMENT INDICATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; BONE MARROW TRANSPLANTATION; CD40 LIGAND; CYCLOPHOSPHAMIDE; DRUG SYNERGISM; GRAFT ENHANCEMENT, IMMUNOLOGIC; GRAFT VS LEUKEMIA EFFECT; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; RADIATION CHIMERA; SAFETY; SKIN TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

ANIMALIA;

EID: 0037244522     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(02)01009-3     Document Type: Article

References (54)

1. Billingham R.E., Brent L., Medawar P.B. "Actively acquired tolerance" of foreign cells. Nature. 172:1953;603-606.
2. Slavin S., Strober S., Fuks Z., Kaplan H.S. Induction of specific tissue transplantation tolerance using fractionated total lymphoid irradiation in adult mice. long-term survival of allogeneic bone marrow and skin grafts J Exp Med. 146:1977;34-48.
3. Slavin S., Reitz B., Bieber C.P., Kaplan H.S., Strober S. Transplantation tolerance in adult rats using total lymphoid irradiation. permanent survival of skin, heart, and marrow allografts J Exp Med. 147:1978;700-707.
4. Sykes M., Sachs D.H. Mixed allogeneic chimerism as an approach to transplantation tolerance. Immunol Today. 9:1988;23-27.
5. Weiden P.L., Sullivan K.M., Flournoy N., Storb R., Thomas E.D. Antileukemic effect of chronic graft-vs-host disease. contribution to improved survival after allogeneic marrow transplantation N Engl J Med. 304:1981;1529-1533.
6. Slavin S., Or R., Naparstek E.et al. Allogeneic bone marrow transplantation without graft-vs-host disease. true tolerance of graft against the host through depletion of donor T lymphocytes pregrafting in malignant and nonmalignant disorders Transplant Proc. 19:1987;2614-2615.
7. Horowitz M.M., Gale R.P., Sondel P.M.et al. Graft-vs-leukemia reactions after bone marrow transplantation. Blood. 75:1990;555-562.
8. Bachar-Lustig E., Rachamim N., Li H.W., Lan F., Reisner Y. Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nat Med. 1:1995;1268-1273.
9. Clift R.A., Buckner C.D., Appelbaum F.R.et al. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase. a randomized trial of two irradiation regimens Blood. 77:1991;1660-1665.
10. Slavin S., Nagler A., Naparstek E.et al. Immunotherapy of leukemia in conjunction with nonmyeloablative conditioning. engraftment of blood stem cells and eradication of host leukemia with nonmyeloablative conditioning based on fludarabine and anti-thymocyte globulin (ATG) Blood. 88:1996;614a. [abstract].
11. Przepiorka D., Anderlini P., Ippoliti C.et al. Allogeneic blood stem cell transplantation in advanced hematologic cancers. Bone Marrow Transplant. 19:1997;455-460.
12. Sykes M., Szot G.L., Swenson K.A., Pearson D.A. Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning. Nat Med. 3:1997;783-787.
13. Hill G.R., Crawford J.M., Cooke K.R., Brinson Y.S., Pan L., Ferrara J.L. Total body irradiation and acute graft-vs-host disease. the role of gastrointestinal damage and inflammatory cytokines Blood. 90:1997;3204-3213.
14. Lee L.A., Sergio J.J., Sykes M. Natural killer cells weakly resist engraftment of allogeneic, long-term, multilineage-repopulating hematopoietic stem cells. Transplantation. 61:1996;125-132.
15. Weiss L., Slavin S. Prevention and treatment of graft-vs-host disease by down-regulation of anti-host reactivity with veto cells of host origin. Bone Marrow Transplant. 23:1999;1139-1143.
16. Blazar B.R., Lees C.J., Martin P.J.et al. Host T cells resist graft-vs-host disease mediated by donor leukocyte infusions. J Immunol. 165:2000;4901-4909.
17. Prigozhina T.B., Gurevitch O., Slavin S. Nonmyeloablative conditioning to induce bilateral tolerance after allogeneic bone marrow transplantation in mice. Exp Hematol. 27:1999;1503-1510.
18. Slavin S., Nagler A., Naparstek E.et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 91:1998;756-763.
19. de Vries-van der Zwan A., Besseling A.C., de Waal L.P., Boog C.J. Specific tolerance induction and transplantation. a single-day protocol Blood. 89:1997;2596-2601.
20. Carella A.M., Champlin R., Slavin S., McSweeney P., Storb R. Mini-allografts. ongoing trials in humans Bone Marrow Transplant. 25:2000;345-350.
21. Childs R., Chernoff A., Contentin N.et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 343:2000;750-758.
22. Wekerle T., Sayegh M.H., Ito H.et al. Anti-CD154 or CTLA4Ig obviates the need for thymic irradiation in a nonmyeloablative conditioning regimen for the induction of mixed hematopoietic chimerism and tolerance. Transplantation. 68:1999;1348-1355.
23. Prigozhina T.B., Gurevitch O., Morecki S., Yakovlev E., Elkin G., Slavin S. Nonmyeloablative allogeneic bone marrow transplantation as immunotherapy for hematologic malignancies and metastatic solid tumors in preclinical models. Exp Hematol. 30:2002;89-96.
24. Chernyakhovskaya I., Yu Nagurskaya E.V., Shaposhnikova G.B., Prigozhina T.B., Fontalin L.N. Tolerance to allogeneic and to xenogeneic heart grafts provided by thymectomy of adult mice combined with donor cell and cyclophosphamide inoculation. Transplantation. 29:1980;409-412.
25. Chernyakhovskaya I., Yu Prigozhina T.B., Nagurskaya E.V., Fontalin L.N. Immunological status of mice with long-standing allogeneic or xenogeneic neonatal heart grafts. Transplantation. 38:1984;267-272.
26. Shin T., Mayumi H., Himeno K., Sunui H., Nomoto K. Drug-induced tolerance to allografts in mice. I. Difference between tumor and skin grafts. Transplantation. 37:1984;580-584.
27. Mayumi H., Himeno K., Shin T., Nomoto K. Drug-induced tolerance to allografts in mice. VI. Tolerance induction in H-2-haplotype identical strain combinations in mice. Transplantation. 40:1985;188-194.
28. Mayumi H., Umesue M., Nomoto K. Cyclophosphamide-induced immunological tolerance. an overview Immunobiology. 195:1996;129-139.
29. Prigozhina T.B., Gurevitch O., Zhu J., Slavin S. Permanent and specific transplantation tolerance induced by a non-myeloablative treatment to a wide variety of allogeneic tissues. I. Induction of tolerance by a short course of total lymphoid irradiation and selective elimination of the donor-specific host lymphocytes. Transplantation. 63:1997;1394-1399.
30. Busutti L., Breccia A., Stagni G., Gattavecchia E. Clinical trials with cyclophosphamide and misonidazole combination for maintaining treatment after radiation therapy of lung carcinoma. Int J Radiat Oncol Biol Phys. 10:1984;1739-1743.
31. Lewkow L.M., Hooker J.L., Movahed A. Cardiac complications of intensive dose mitoxantrone and cyclophosphamide with autologous bone marrow transplantation in metastatic breast cancer. Int J Cardiol. 34:1992;273-276.
32. + T cells play a critical role in co-stimulatory blockade-resistant allograft rejection. J Clin Invest. 104:1999;1715-1722.
33. Williams M.A., Trambley J., Ha J.et al. Genetic characterization of strain differences in the ability to mediate CD40/CD28-independent rejection of skin allografts. J Immunol. 165:2000;6849-6857.
34. Ito H., Kurtz J., Shaffer J., Sykes M. CD4 T cell-mediated alloresistance to fully MHC-mismatched allogeneic bone marrow engraftment is dependent on CD40-CD40 ligand interactions, and lasting T cell tolerance is induced by bone marrow transplantation with initial blockade of this pathway. J Immunol. 166:2001;2970-2981.
35. Iwakoshi N.N., Markees T.G., Turgeon N.et al. Skin allograft maintenance in a new synchimeric model system of tolerance. J Immunol. 167:2001;6623-6630.
36. Noelle R.J., Roy M., Shepherd D.M., Stamenkovic I., Ledbetter J.A., Aruffo A. A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc Natl Acad Sci U S A. 89:1992;6550-6554.
37. Linsley P.S., Brady W., Urnes M., Grosmaire L.S., Damle N.K., Ledbetter J.A. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med. 174:1991;561-569.
38. Slavin S., Strober S. Spontaneous murine B-cell leukaemia. Nature. 272:1978;624-626.
39. Seung E., Iwakoshi N., Woda B.A.et al. Allogeneic hematopoietic chimerism in mice treated with sublethal myeloablation and anti-CD154 antibody. absence of graft-vs-host disease, induction of skin allograft tolerance, and prevention of recurrent autoimmunity in islet-allografted NOD/Lt mice Blood. 95:2000;2175-2182.
40. Omoto K., Nishimura Y., Nomoto K.et al. Anti-CD4 monoclonal antibody reduces the dose of cyclophosphamide required to induce tolerance to H-2 haplotype identical skin allografts in mice. Immunobiology. 195:1996;16-32.
41. Jardine I., Fenselau C., Appler M., Kan M.N., Brundrett R.B., Colvin M. Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy. Cancer Res. 38:1978;408-415.
42. Ding L., Green J.M., Thompson C.B., Shevach E.M. B7/CD28-dependent and -independent induction of CD40 ligand expression. J Immunol. 155:1995;5124-5132.
43. Kennedy M.K., Picha K.S., Fanslow W.C.et al. CD40/CD40 ligand interactions are required for T cell-dependent production of interleukin-12 by mouse macrophages. Eur J Immunol. 26:1996;370-378.
44. Gately M.K., Desai B.B., Wolitzky A.G.et al. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol. 147:1991;874-882.
45. Germann T., Gately M.K., Schoenhaut D.S.et al. Interleukin-12/T cell stimulating factor, a cytokine with multiple effects on T helper type 1 (Th1) but not on Th2 cells. Eur J Immunol. 23:1993;1762-1770.
46. Li Y., Li X.C., Zheng X.X., Wells A.D., Turka L.A., Strom T.B. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med. 5:1999;1298-1302.
47. Clark L.B., Foy T.M., Noelle R.J. CD40 and its ligand. Adv Immunol. 63:1996;43-78.
48. + CTL response. J Exp Med. 183:1996;2129-2142.
49. Bennett S.R., Carbone F.R., Karamalis F., Flavell R.A., Miller J.F., Heath W.R. Help for cytotoxic T-cell responses is mediated by CD40 signalling. Nature. 393:1998;478-480.
50. Smiley S.T., Csizmadia V., Gao W., Turka L.A., Hancock W.W. Differential effects of cyclosporine A, methylprednisolone, mycophenolate, and rapamycin on CD154 induction and requirement for NFκB. implications for tolerance induction Transplantation. 70:2000;415-419.
51. Pelot M.R., Pearson D.A., Swenson K.et al. Lymphohematopoietic graft-vs-host reactions can be induced without graft-vs-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen. Biol Blood Marrow Transplant. 5:1999;133-143.
52. Taylor P.A., Lees C.J., Waldmann H., Noelle R.J., Blazar B.R. Requirements for the promotion of allogeneic engraftment by anti-CD154 (anti-CD40L) monoclonal antibody under nonmyeloablative conditions. Blood. 98:2001;467-474.
53. + T cells in draining lymph nodes in the presence of apoptotic tumor cells. J Immunol. 167:2001;5678-5688.
54. Sotomayor E.M., Borrello I., Tubb E.et al. Conversion of tumor-specific CD41 T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med. 5:1999;780-787.